Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory

Analysis of RCT (n=1566) found that radiological response (both in RECIST and GCIG CA125 criteria) to neoadjuvant chemotherapy should not be used as a predictive marker for those who would benefit from surgery, as surgery was potentially beneficial regardless of response.

Source:

The Lancet Oncology